Non-alcoholic fatty liver disease epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
(6 intermediate revisions by 2 users not shown)
Line 4: Line 4:
   
   
==Overview==
==Overview==
In the third [[National Health and Nutrition Examination Survey]] (NHANES III), the peak prevalence of [[NAFLD]] in men occurred in the fourth decade and in the sixth decade for women.NAFLD is associated with visceral obesity and diabetes. It has mirrored the epidemiologic course of obesity in the US and is detected in 73–90% of obese individuals on biopsy. Approximately 1/3 of the usa population are estimated to have NAFL. Through most estimates, NASH accommodates approximately 15% of all NAFLD and 3–5% of the american populace.
The  estimated annual incidence of non alcoholic liver disease with steatosis in the United States is approximately 9,255 per 100,000 individuals. The prevalence of non-alcoholic liver disease in the United States is estimated to be 10,000 to 24,000 cases per 100,000 individuals annually. Non-alcoholic fatty liver disease may occur at any age, but is diagnosed most commonly in patients aged 50 to 60 years. [[Hepatic]] [[steatosis]] is more prevalent in the hispanics.  


==Epidemiology and Demographics==
==Epidemiology ==


==Epidemiology==
=== Incidence ===
* NAFLD is associated with visceral obesity and diabetes.  
* The  estimated annual incidence of non alcoholic liver disease with steatosis in the United States is approximately 9,255 per 100,000 individuals.
* It has reflected the epidemiologic direction of weight problems inside the US and is detected in 73–90% of obese people on biopsy.
* The  estimated annual incidence of non alcoholic liver disease with steatohepatitis in the United States is approximately 265 per 100,000 individuals .
* About 1/3 of america population are expected to have NAFL. with the aid of maximum estimates, NASH contains about 15% of all NAFLD and 3–5% of the american populace.  
 
* Hospitalizations for NAFLD have elevated by means of 97%.<ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref>
* About 1/3 of america population is expected to have non alcoholic fatty liver disease.<ref name="pmid20460905">{{cite journal| author=Bellentani S, Scaglioni F, Marino M, Bedogni G| title=Epidemiology of non-alcoholic fatty liver disease. | journal=Dig Dis | year= 2010 | volume= 28 | issue= 1 | pages= 155-61 | pmid=20460905 | doi=10.1159/000282080 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20460905  }} </ref><ref name="pmid25514916">{{cite journal| author=Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M| title=Non alcoholic fatty liver: epidemiology and natural history. | journal=Rev Recent Clin Trials | year= 2014 | volume= 9 | issue= 3 | pages= 126-33 | pmid=25514916 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25514916  }} </ref><ref name="pmid28346543">{{cite journal| author=Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC et al.| title=Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. | journal=PLoS One | year= 2017 | volume= 12 | issue= 3 | pages= e0173499 | pmid=28346543 | doi=10.1371/journal.pone.0173499 | pmc=5367688 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28346543  }} </ref><ref name="pmid19014878">{{cite journal| author=Fan JG, Farrell GC| title=Epidemiology of non-alcoholic fatty liver disease in China. | journal=J Hepatol | year= 2009 | volume= 50 | issue= 1 | pages= 204-10 | pmid=19014878 | doi=10.1016/j.jhep.2008.10.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19014878  }} </ref><ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref>  


===Prevalance===
===Prevalance===
* As the prevalence of fatty liver ailment increases, clinicians can have greater equipment at hand for control of this condition.
* The prevalence of non-alcoholic liver disease in the United States is estimated to be 10,000 to 24,000 cases per 100,000 individuals annually.
* We conclude the horizon is vibrant for sufferers and docs who address NAFLD.<ref name="pmid285079292">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref>
 
* In obese children the prevalence of non-alcoholic liver disease is estimated to be 20,000 to 50,000 cases per 100,000 individuals annually.<ref name="pmid285079292">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref>
 
* Prevalence of non-alcoholic fatty liver disease increases nearly five fold in obese individuals.
 
== Demographics ==
 
=== Age ===
* Non-alcoholic fatty liver disease may occur at any age, but is diagnosed most commonly in patients aged 50 to 60 years.
 
=== Gender ===
* Men are more commonly affected by non-alcoholic liver disease than women.
* Among women it is more common in post-menopausal women than pre-menopausal.


===Ethinicity===
===Race===
* [[Hepatic]] [[steatosis]] was found in 45% of [[hispanics]] (both men and women), 33% of caucasians (42% of men, 24% of women) and 24% of african-american (23% of men, 24% of women).
* [[Hepatic]] [[steatosis]] is more prevalent in the hispanics (45%) race and followed by caucasians (42% of men, 24% of women) and african-american (24%)
* This pattern may hold true in children as well. In a San Diego study of 742 consecutive [[autopsy|autopsies]] of children victims of trauma over 10 years, [[fatty live]]r was found in 9.6% of all children, 38% of the [[obese]], 12% of hispanics, 10% of asians, 8.6% of caucasians and 1.5% of african-americans.<ref name="pmid24868321">{{cite journal |vauthors=Pan JJ, Fallon MB |title=Gender and racial differences in nonalcoholic fatty liver disease |journal=World J Hepatol |volume=6 |issue=5 |pages=274–83 |year=2014 |pmid=24868321 |pmc=4033285 |doi=10.4254/wjh.v6.i5.274 |url=}}</ref>


==References==
==References==

Revision as of 21:19, 22 December 2017

Non-Alcoholic Fatty Liver Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-alcoholic fatty liver disease epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease epidemiology and demographics

CDC on Non-alcoholic fatty liver disease epidemiology and demographics

Non-alcoholic fatty liver disease epidemiology and demographics in the news

Blogs on Non-alcoholic fatty liver disease epidemiology and demographics

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

The estimated annual incidence of non alcoholic liver disease with steatosis in the United States is approximately 9,255 per 100,000 individuals. The prevalence of non-alcoholic liver disease in the United States is estimated to be 10,000 to 24,000 cases per 100,000 individuals annually. Non-alcoholic fatty liver disease may occur at any age, but is diagnosed most commonly in patients aged 50 to 60 years. Hepatic steatosis is more prevalent in the hispanics.

Epidemiology

Incidence

  • The estimated annual incidence of non alcoholic liver disease with steatosis in the United States is approximately 9,255 per 100,000 individuals.
  • The estimated annual incidence of non alcoholic liver disease with steatohepatitis in the United States is approximately 265 per 100,000 individuals .
  • About 1/3 of america population is expected to have non alcoholic fatty liver disease.[1][2][3][4][5]

Prevalance

  • The prevalence of non-alcoholic liver disease in the United States is estimated to be 10,000 to 24,000 cases per 100,000 individuals annually.
  • In obese children the prevalence of non-alcoholic liver disease is estimated to be 20,000 to 50,000 cases per 100,000 individuals annually.[6]
  • Prevalence of non-alcoholic fatty liver disease increases nearly five fold in obese individuals.

Demographics

Age

  • Non-alcoholic fatty liver disease may occur at any age, but is diagnosed most commonly in patients aged 50 to 60 years.

Gender

  • Men are more commonly affected by non-alcoholic liver disease than women.
  • Among women it is more common in post-menopausal women than pre-menopausal.

Race

  • Hepatic steatosis is more prevalent in the hispanics (45%) race and followed by caucasians (42% of men, 24% of women) and african-american (24%)

References

  1. ↑ Bellentani S, Scaglioni F, Marino M, Bedogni G (2010). "Epidemiology of non-alcoholic fatty liver disease". Dig Dis. 28 (1): 155–61. doi:10.1159/000282080. PMID 20460905.
  2. ↑ Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M (2014). "Non alcoholic fatty liver: epidemiology and natural history". Rev Recent Clin Trials. 9 (3): 126–33. PMID 25514916.
  3. ↑ Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC; et al. (2017). "Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States". PLoS One. 12 (3): e0173499. doi:10.1371/journal.pone.0173499. PMC 5367688. PMID 28346543.
  4. ↑ Fan JG, Farrell GC (2009). "Epidemiology of non-alcoholic fatty liver disease in China". J Hepatol. 50 (1): 204–10. doi:10.1016/j.jhep.2008.10.010. PMID 19014878.
  5. ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
  6. ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.

Template:WS Template:WH

Retrieved from "https://www.wikidoc.org/index.php?title=Non-alcoholic_fatty_liver_disease_epidemiology_and_demographics&oldid=1424506"